- Home
- RCUS
as of 12-05-2025 3:45pm EST
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 3.1B | IPO Year: | 2018 |
| Target Price: | $28.88 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $26.40 | Next Earning Date: | 10-28-2025 |
| Revenue: | $240,000,000 | Revenue Growth: | -8.74% |
| Revenue Growth (this year): | -5.86% | Revenue Growth (next year): | -41.20% |
AI-Powered RCUS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arcus Biosciences Inc. (RCUS)
President
Avg Cost/Share
$24.71
Shares
82,997
Total Value
$2,050,598.58
Owned After
954,063
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$26.00
Shares
1,900
Total Value
$49,400.00
Owned After
27,363
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$25.00
Shares
5,000
Total Value
$125,000.00
Owned After
87,138
SEC Form 4
President
Avg Cost/Share
$19.75
Shares
5,050
Total Value
$99,737.50
Owned After
954,063
SEC Form 4
President
Avg Cost/Share
$20.47
Shares
44,950
Total Value
$913,026.79
Owned After
954,063
Chief Operating Officer
Avg Cost/Share
$18.97
Shares
50,291
Total Value
$954,065.53
Owned After
214,232
SEC Form 4
President
Avg Cost/Share
$20.32
Shares
4,314
Total Value
$87,649.69
Owned After
954,063
SEC Form 4
President
Avg Cost/Share
$21.35
Shares
77,840
Total Value
$1,626,634.21
Owned After
954,063
President
Avg Cost/Share
$20.19
Shares
19,019
Total Value
$383,944.16
Owned After
954,063
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$20.00
Shares
5,000
Total Value
$100,000.00
Owned After
87,138
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Jaen Juan C. | RCUS | President | Dec 4, 2025 | Sell | $24.71 | 82,997 | $2,050,598.58 | 954,063 | |
| Azoy Alexander | RCUS | Chief Accounting Officer | Nov 26, 2025 | Sell | $26.00 | 1,900 | $49,400.00 | 27,363 | |
| Goeltz II Robert C. | RCUS | Chief Financial Officer | Nov 26, 2025 | Sell | $25.00 | 5,000 | $125,000.00 | 87,138 | |
| Jaen Juan C. | RCUS | President | Nov 18, 2025 | Sell | $19.75 | 5,050 | $99,737.50 | 954,063 | |
| Jaen Juan C. | RCUS | President | Nov 17, 2025 | Sell | $20.47 | 44,950 | $913,026.79 | 954,063 | |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Nov 7, 2025 | Sell | $18.97 | 50,291 | $954,065.53 | 214,232 | |
| Jaen Juan C. | RCUS | President | Oct 30, 2025 | Sell | $20.32 | 4,314 | $87,649.69 | 954,063 | |
| Jaen Juan C. | RCUS | President | Oct 29, 2025 | Sell | $21.35 | 77,840 | $1,626,634.21 | 954,063 | |
| Jaen Juan C. | RCUS | President | Oct 28, 2025 | Sell | $20.19 | 19,019 | $383,944.16 | 954,063 | |
| Goeltz II Robert C. | RCUS | Chief Financial Officer | Oct 28, 2025 | Sell | $20.00 | 5,000 | $100,000.00 | 87,138 |
Compare RCUS vs Leading Stocks
See how RCUS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RCUS Arcus Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.